- Home
- LUNG vs ICCM Comparison
LUNG vs ICCM Comparison
Compare LUNG & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ICCM
- Stock Information
- Founded
- LUNG 1995
- ICCM 2006
- Country
- LUNG United States
- ICCM Israel
- Employees
- LUNG N/A
- ICCM N/A
- Industry
- LUNG Industrial Specialties
- ICCM
- Sector
- LUNG Health Care
- ICCM
- Exchange
- LUNG Nasdaq
- ICCM Nasdaq
- Market Cap
- LUNG 65.6M
- ICCM 61.1M
- IPO Year
- LUNG 2020
- ICCM N/A
- Fundamental
- Price
- LUNG $1.55
- ICCM $1.02
- Analyst Decision
- LUNG Buy
- ICCM Strong Buy
- Analyst Count
- LUNG 7
- ICCM 1
- Target Price
- LUNG $7.66
- ICCM $2.00
- AVG Volume (30 Days)
- LUNG 480.4K
- ICCM 2.2M
- Earning Date
- LUNG 10-29-2025
- ICCM 08-13-2025
- Dividend Yield
- LUNG N/A
- ICCM N/A
- EPS Growth
- LUNG N/A
- ICCM N/A
- EPS
- LUNG N/A
- ICCM N/A
- Revenue
- LUNG $90,549,000.00
- ICCM $2,787,000.00
- Revenue This Year
- LUNG $10.30
- ICCM $3.95
- Revenue Next Year
- LUNG $14.72
- ICCM $266.15
- P/E Ratio
- LUNG N/A
- ICCM N/A
- Revenue Growth
- LUNG 18.24
- ICCM N/A
- 52 Week Low
- LUNG $1.47
- ICCM $0.48
- 52 Week High
- LUNG $9.37
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- LUNG 37.40
- ICCM 51.92
- Support Level
- LUNG $1.60
- ICCM $0.98
- Resistance Level
- LUNG $1.76
- ICCM $1.11
- Average True Range (ATR)
- LUNG 0.13
- ICCM 0.06
- MACD
- LUNG 0.02
- ICCM -0.00
- Stochastic Oscillator
- LUNG 2.86
- ICCM 12.12
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.